Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Body mass index in young men and risk of inflammatory bowel disease through adult life: A population-based Danish cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Polygenic predisposition to breast cancer and the risk of coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Reappraisal of variants previously linked with sudden infant death syndrome: results from three population-based cohorts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Lifelines Cohort authors
Vis graf over relationer

BACKGROUND: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9.

METHODS: Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration.

RESULTS: The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57; 1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer's disease - outcomes for which large-scale trial data were unavailable.

CONCLUSIONS: Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown; although precision was moderate.

OriginalsprogEngelsk
Artikelnummer240
TidsskriftBMC Cardiovascular Disorders
Vol/bind19
Udgave nummer1
Sider (fra-til)240
ISSN1471-2261
DOI
StatusUdgivet - 29 okt. 2019

ID: 58249073